MAGEA9: A Potential Drug Target and Biomarker for Melanoma (G4108)

Target Name: MAGEA9

NCBI ID: G4108

MAGEA9

MAGEA9: A Potential Drug Target and Biomarker for Melanoma

Melanoma is a type of skin cancer that is often aggressive and can be deadly if left untreated. Despite advances in treatment, the survival rate for melanoma remains high due to the lack of effective targeted therapies. The MAGEA9 protein is a potential drug target and biomarker for melanoma that has been identified by researchers. In this article, we will explore the biology of MAGEA9 and its potential as a drug target and biomarker for melanoma.

The MAGEA9 Protein

MAGEA9 is a transmembrane protein that is expressed in various tissues, including skin, hair, and nails. It is a member of the melanoma antigen family (MAAF), which consists of nine proteins that are involved in the development and progression of melanoma. MAGEA9 is a 21-kDa protein that consists of a N-terminus, a transmembrane segment, and a C-terminus. The N-terminus of MAGEA9 contains a putative transmembrane anchoring region that is involved in the protein's stability and localization to the membrane. C-terminus of MAGEA9 contains a potential N-endonuclease domain that is involved in the protein's hydrolytic activity.

MAGEA9 is involved in various cellular processes that are relevant to melanoma development, including cell growth, apoptosis, and angiogenesis. It has been shown to be involved in the regulation of cell proliferation, differentiation, and survival. MAGEA9 has also been shown to be involved. in the regulation of cell death, as it has been shown to induce cell apoptosis in melanoma cells.

In addition to its role in cell death, MAGEA9 has also been shown to be involved in the regulation of cell survival. It has been shown to play a role in the regulation of cell growth, as well as the regulation of cell cycle progression. MAGEA9 has also been shown to be involved in the regulation of angiogenesis, as it has been shown to promote the formation of new blood vessels in response to the growth of a tumor.

MAGEA9 as a Drug Target

MAGEA9 has been identified as a potential drug target for melanoma due to its involvement in various cellular processes that are relevant to the development and progression of melanoma. One of the potential mechanisms by which MAGEA9 can be targeted is through its role in cell death.

MAGEA9 has been shown to induce cell apoptosis in melanoma cells, which can also be an effective form of cancer treatment. In addition, MAGEA9 has been shown to play a role in the regulation of cell cycle progression, which can also be an effective form of cancer treatment. treatment. For example, MAGEA9 has been shown to inhibit the progression of the cell cycle, which can lead to the inhibition of cell proliferation and the inhibition of the formation of new blood vessels that can support the growth of a tumor.

Another potential mechanism by which MAGEA9 can be targeted is through its role in the regulation of angiogenesis. MAGEA9 has been shown to promote the formation of new blood vessels in response to the growth of a tumor, which can be an effective form of cancer treatment. For example, MAGEA9 has been shown to increase the production of vascular endothelial growth factor (VEGF) in response to the growth of a tumor, which can lead to the formation of new blood vessels.

MAGEA9 as a Biomarker

MAGEA9 has also been shown to be potential biomarker for

Protein Name: MAGE Family Member A9

Functions: Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression

The "MAGEA9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGEA9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets